TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00548548
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
Study: NCT04326738
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
Study: NCT02456129
Drug: Vilaprisan (BAY1002670)
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
Study: NCT02456129
Drug: [14C] Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
Study: NCT00419744
Drug: Budesonide/formoterol (SYMBICORT) pMDI
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00419744
Drug: Formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00548548
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
Study: NCT04281667
Drug: Mechanical Bowel Preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
Study: NCT00725985
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.
Study: NCT03548129
Drug: phosphomycin
Normalized name: Phosphomycin
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
Study: NCT03548129
Drug: Culture specific antibiotic therapy
Normalized name: casein, emmental cultured
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture-specific antibiotic treatment for 5 days
Study: NCT01018602
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 100 mg per day over 24 months
Study: NCT01018602
Drug: inactive pill
Normalized name: activated charcoal Pill
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day over 24 months
Study: NCT00056823
Drug: rhuFab V2 (ranibizumab)
Normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03700229
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
Study: NCT03700229
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab intravenously 500 mg for one dose
Study: NCT00672997
Drug: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00672997
Drug: Travoprost 0.004%/Timolol 0.5% ophthalmic solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02008617
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Study: NCT02008617
Drug: Preservative free normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Study: NCT00673920
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.
Study: NCT03318094
Drug: Phentolamine
Normalized name: Phentolamine
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrabrachial phentolamine will be given on the blocked day
Study: NCT03318094
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
Study: NCT00285051
Drug: inhaled delta-8-THC 300mcg or 600mcg per dose
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC
Study: NCT02791243
Drug: Finasteride 0.25%
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cutaneous solution of finasteride 0.25%
Study: NCT02791243
Drug: Placebo for Finasteride 0.25%
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vehicle cutaneous solution of P-3074
Study: NCT02791243
Drug: Negative Control
Normalized name: GLYCERIN NEGATIVE CONTROL
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% aqueous NaCl
Study: NCT02908711
Drug: 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
Study: NCT01198626
Drug: JNJ-32729463
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
Study: NCT01198626
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
Study: NCT01198626
Drug: JNJ-32729463 (Open-Label)
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
Study: NCT02002325
Drug: Tissue-type plasminogen activator (alteplase)
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
Study: NCT04485702
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg IV
Study: NCT04485702
Drug: Ketamine Injectable Product
Normalized name: ketamine Injectable Product
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6mg IV
Study: NCT04485702
Drug: MELT-100
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: midazolam 3mg and ketamine 25mg SL tablet
Study: NCT01416025
Drug: Prospective TDM Arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Study: NCT01352884
Drug: AMP-224
Normalized name: AMP-224
DrugBank: AMP-224 (DB15767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of AMP-224
Study: NCT01352884
Drug: AMP-224
Normalized name: AMP-224
DrugBank: AMP-224 (DB15767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
Study: NCT04879407
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any rivaroxaban dispensing claim is used as the exposure group
Study: NCT04879407
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any warfarin dispensing claim is used as the reference group
Study: NCT02519842
Drug: Fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02519842
Drug: Placebo for fosaprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02519842
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02519842
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02519842
Drug: 5-HT3 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00187109
Drug: Recombinant Human Thrombopoietin
Normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01146288
Drug: Acetazolamide first, then Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
Study: NCT01292083
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01561976
Drug: Metformin hydrochloride prolonged release
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000mg in fasting state
Study: NCT01561976
Drug: metformin hydrochloride prolonged release
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000mg in fed state
Study: NCT01561976
Drug: Metformin hydrochloride sustained release/Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000/2mg in fed state
Study: NCT03037970
Drug: RhPDGF-BB
Normalized name: rhPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
Study: NCT00641264
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03278522
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
Study: NCT00823797
Drug: Bendamustine Hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01461460
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet 400 mg Moxifloxacin
Study: NCT03781479
Drug: Amifampridine Phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Study: NCT04635852
Drug: Immediate release morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02921256
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02921256
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02340195
Drug: Idalopirdine (Lu AE58054) 60 mg
Normalized name: Lu-DOTA-TATE
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: encapsulated film-coated tablets for oral use once daily for 10 days
Study: NCT01448616
Drug: TDF
Normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Study: NCT04661527
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
Study: NCT05755750
Drug: Genipin
Normalized name: Genipin
DrugBank: Genipin (DB19124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratendinous genipin injection
Study: NCT02244515
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
Study: NCT01983111
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage and administration: This one patch should be attached every 7 days.
Study: NCT02009787
Drug: vitamin D3 tablets
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU vitamin D3 tablets were taken daily for 6 months
Study: NCT04380142
Drug: ABBV-951
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for continuous subcutaneous infusion (CSCI)
Study: NCT00737360
Drug: TAS-106
Normalized name: TAS-106
DrugBank: TAS-106 (DB06656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT01675947
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
Study: NCT01675947
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 2%
Study: NCT00654732
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00654732
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00654732
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01772940
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
Study: NCT01772940
Drug: ritonavir-boosted Lopinavir
Normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
Study: NCT01772940
Drug: Tenofovir/emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
Study: NCT01772940
Drug: Zidovudine/lamivudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
Study: NCT00305396
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03880357
Drug: Betamethasone Scalp Suspension 0.064%;0.0005%
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study: NCT01090752
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Study: NCT00946712
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03577457
Drug: oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal administration of oxytocin (24 IU)
Study: NCT00814255
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
Study: NCT00814255
Drug: Lisinopril, losartan, and atorvastatin
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
Study: NCT01090752
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Study: NCT00814255
Drug: galactose
Normalized name: Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
Study: NCT03346837
Drug: BMS-986205
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986205
Study: NCT03346837
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: NCT03346837
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01734902
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar coated tablets for oral administration
Study: NCT01734902
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drops for oral administration
Study: NCT00946712
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03583138
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To provide buprenorphine for 12 months for those who are interested in receiving it.
Study: NCT04430998
Drug: Zinc L-Carnosine
Normalized name: L-Carnosine
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
Study: NCT04430998
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
Study: NCT00758563
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT00758563
Drug: Triclosan/Fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT01463033
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 55 mg/kg/day given in 2 divided doses 12 hours apart
Study: NCT03485157
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 1 mL 0.9% Sodium Chloride, USP
Study: NCT00399087
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine oral administration
Study: NCT00399087
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV administration